Five upcoming psychedelic clinical trials you don’t want to miss

1. A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders (MED1)

Organised by MAPS, this Phase II study will explore the safety and feasibility of MDMA-assisted therapy (MDMA-AT) in the treatment of 18 participants with eating disorders.

2. An Open-Label, Phase 2, Feasibility Study of Manualized MDMA-Assisted Psychotherapy in Subjects with Major Depressive Disorder

The PsykForsk research team at Østfold hospital in Norway will conduct the world’s first trial using investigating MDMA-AT in people with major depressive disorder (MDD).

3. Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder

Tryp Therapeutics is planning a Phase IIa open-label study to determine the safety and feasibility of a single dose of their psilocybin formulation, TRP-8802, in people with binge eating disorder.

4. Study of the Safety and Feasibility of Psilocybin in Adults With Methamphetamine Use Disorder

Revive Therapeutics & the University of Wisconsin-Madison will investigate the safety and feasibility of two oral doses of psilocybin when combined with behavioural support for methamphetamine use disorder (MUD).

5. Effects of Psilocybin in Post-Treatment Lyme Disease

Researchers at Johns Hopkins University will examine the effects of psilocybin on Lyme disease symptom burden and quality of life in people with Post-Treatment Lyme Disease (PTLD).



Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store


Psychedelics information for everyone. Making info about psychedelics more accessible!